Fenofibrate
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Fenofibrate: From Hyperlipidemia to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Fenofibrate is a fibrate-class PPARα agonist with an established role in treating hyperlipidemia and mixed dyslipidemia. The TxGNN model predicts it may also be effective for Homozygous Familial Hypercholesterolemia (HoFH), but this direction is currently supported by only 1 clinical trial (which actually tested a different drug in the same patient population) and 11 publications, most of which are indirect or mechanistic in nature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hyperlipidemia / mixed dyslipidemia (established fibrate-class use; no India label text available — see Market Information below) |
| Predicted New Indication | Homozygous Familial Hypercholesterolemia (HoFH) |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for fenofibrate is not available in this evidence pack (marked as a data gap, DG002). Based on known pharmacology, fenofibrate is a PPARα agonist that upregulates lipoprotein lipase and reduces apoC-III, which lowers triglycerides and modestly raises HDL-cholesterol — this is the mechanism underlying its established use in hyperlipidemia and mixed dyslipidemia.
HoFH, however, is caused by a near-complete absence or dysfunction of LDL receptors, meaning affected patients cannot adequately clear LDL through the receptor-dependent pathway regardless of triglyceride-lowering therapy. Effective HoFH treatments (e.g., PCSK9 inhibitors, ANGPTL3 inhibitors, MTP inhibitors, LDL apheresis) work through LDL-receptor-independent mechanisms. Fenofibrate’s PPARα mechanism does not address this core defect — it may provide a modest, theoretical adjunct benefit (e.g., triglyceride reduction in patients with mixed lipid abnormalities) but is not expected to meaningfully correct the underlying LDL clearance defect in HoFH.
This mechanistic mismatch is consistent with the evidence found: the only clinical trial associated with this candidate actually tested a different drug (alirocumab, a PCSK9 inhibitor) in HoFH patients, and most supporting literature is general dyslipidemia guidance rather than direct evidence of fenofibrate efficacy in HoFH. One older cohort study does report a single HoFH patient showing a notable cholesterol reduction on fenofibrate, but this is anecdotal (n=1) rather than confirmatory.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03510715 | Phase 3 | Completed | 18 | Evaluated alirocumab (a PCSK9 inhibitor), not fenofibrate, in children/adolescents (8–17y) with HoFH on background therapy; assessed LDL-C reduction at 12/24/48 weeks. Population overlaps with the predicted indication, but the tested drug does not — relevance graded “C” (low direct relevance to fenofibrate). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6593751 | 1984 | Cohort | Pharmacological Research Communications | 22 patients with type II hyperlipoproteinemia treated with fenofibrate 300mg/day for 4–12 months; the single enrolled HoFH patient showed the greatest fall in total and LDL cholesterol among all patients — the only direct fenofibrate-in-HoFH observation in this evidence set. |
| 28437620 | 2017 | Guideline/Review | Endocrine Practice | AACE/ACE clinical practice guideline for dyslipidemia management and cardiovascular disease prevention, providing general context for fibrate use in lipid management. |
| 37979722 | 2024 | Review | Indian Heart Journal | Reviews non-statin lipid-lowering drugs; states fenofibrate’s most definite indication is fasting triglyceride >500 mg/dL to reduce pancreatitis risk, with modest cardiovascular event reduction — supports established use, not HoFH-specific efficacy. |
| 24946816 | 2014 | Case series/Review | Internal Medicine Journal | Discusses liver transplantation for HoFH in the era of emerging lipid-lowering therapies; frames standard lipid-lowering drugs (including fibrates) as generally insufficient for HoFH. |
| 2042836 | 1991 | Review | Annals of the New York Academy of Sciences | Reviews pharmacologic/surgical treatments for dyslipidemic children and adolescents, including familial hypercholesterolemia; lists fenofibrate among agents used with variable success. |
| 26432726 | 2015 | Review | Indian Heart Journal | General review of LDL-cholesterol-lowering therapy (statins, PCSK9 inhibitors); provides background context rather than fenofibrate-specific HoFH data. |
| 35499807 | 2022 | Review | Current Atherosclerosis Reports | Reviews dyslipidemia management in pregnancy; general context, not HoFH-specific. |
| 14620392 | 2003 | Review | Pharmacotherapy | Review of ezetimibe (a different lipid-lowering drug class); tangential background only. |
| 9129869 | 1997 | Review | Drugs | Review of atorvastatin pharmacology; tangential background only. |
| 9627539 | 1998 | Review | The Canadian Journal of Cardiology | Review of atorvastatin in dyslipidemia treatment; tangential background only. |
India Market Information
Fenofibrate currently holds no marketing authorization in India — the evidence pack records 0 registered licenses and a market status of “Not Marketed.” No product name, dosage form, or approved indication text is available for this market.
Safety Considerations
- Drug Interactions: 199 total interactions recorded (source: DDInter), all classified as Moderate severity. The interactions retrieved are predominantly with antidiabetic agents — sulfonylureas (Acetohexamide, Chlorpropamide, Glimepiride, Glipizide, Glyburide) and multiple insulin formulations (human, aspart, degludec, detemir, glargine, glulisine, lispro, and others) — as well as Chenodeoxycholic acid and Esomeprazole. Co-administration with glucose-lowering therapies warrants monitoring for altered glycemic control.
Key warnings and contraindications are not available in this evidence pack (data gap, DG001) — refer to the manufacturer’s package insert for complete safety information once available.
Conclusion and Next Steps
Decision: Hold
Rationale: The only clinical trial associated with this candidate tested a different drug (alirocumab) rather than fenofibrate, and the supporting literature is largely general dyslipidemia background rather than direct evidence of fenofibrate efficacy in HoFH. The mechanistic rationale itself acknowledges that fenofibrate’s PPARα action does not address the core LDL-receptor defect in HoFH, offering at most a theoretical adjunct benefit. This corresponds to an L4 evidence level (mechanism/preclinical-level support only).
To proceed, the following is needed:
- Direct clinical trials or controlled studies testing fenofibrate specifically (not as background/adjunct to other agents) in confirmed HoFH patients
- TFDA/India-equivalent label warnings and contraindications (currently a Blocking data gap, DG001)
- Confirmed mechanism of action data from DrugBank (High-severity data gap, DG002)
- A regulatory pathway assessment, since the drug is not currently marketed or licensed in India
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.